The obvious and inevitable risk of the proposal is that companies will act to innoculate their larger and more lucrative market by not launching or significantly delaying the launch of new medicines in Australia. They may even be forced to consider removing already reimbursed medicines.

Latest Video
New Stories
-
New leadership for AbbVie Australia
December 12, 2019 - - Latest News -
Key trade agreement scraps pharma IP provision
December 12, 2019 - - Latest News -
Still time to take advantage of BioPharmaDispatch 2020 early registration
December 12, 2019 - - Latest News -
MRFF program for issues identified by PBAC
December 12, 2019 - - Latest News -
MA board reappoints Dr Anna Lavelle
December 12, 2019 - - Latest News -
MSD announces US$2.7bn acquisition of ArQule
December 11, 2019 - - Latest News -
Sanofi narrows focus and scraps R&D in heritage areas
December 11, 2019 - - Latest News